Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesGastroenterologyCareSource Georgia WATS3D Coverage Update | OpenPa…
    Ask Trek AI about this page
    CurrentCareSource GeorgiaPolicy MP-AD-1398

    Esophageal Brush Biopsy

    Customize your policy alerts

    Sign up for caresourcegeorgia Policy MP-AD-1398 alerts

    Get alerted when Policy MP-AD-1398 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This administrative policy governs coverage of esophageal brush biopsy, including WATS3D, for CareSource Marketplace members in Georgia, Ohio, and West Virginia. WATS3D is considered experimental and investigational, and claims for esophageal brush biopsy will be denied.

    Policy Summary
    PayerCareSource Georgia
    PolicyEsophageal Brush Biopsy
    Policy CodePolicy MP-AD-1398
    Change TypeAdministrative updateno material clinical or coverage change
    Effective DateDecember 1, 2026
    Next Review DateN/A
    Key ActionPresent complete service and medical-necessity documentation when requested by CareSource.
    SourceLink
    POLICY UPDATE CHANGES

    References were updated during the policy revision history.

    Statistics and minor policy edits were updated during the August 26, 2026 revision.

    5%-12%Chronic GERD patients with Barrett’s esophagus
    22,530Estimated new esophageal cancer cases in 2026
    >16,000Predicted esophageal cancer fatalities in 2026
    1Known precursor lesion of esophageal adenocarcinoma

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Coverage Criteria

    WATS3D Esophageal Brush Biopsy

    CareSource considers esophageal brush biopsy using wide-area transepithelial sampling with computer-assisted three-dimensional analysis (WATS3D) experimental and investigational due to insufficient evidence.

    Policy determination and claim handling

    • WATS3D esophageal brush biopsy is experimental and investigational for screening, diagnosis, or surveillance of cancerous or pre-cancerous esophageal lesions.
    • Any claims for esophageal brush biopsy will be denied.

      This denial rule applies to claims for esophageal brush biopsy, including WATS3D.

    • CareSource may request documentation of services performed. Appropriate and complete documentation must be presented at the time of review to validate medical necessity.

      If medical necessity is not confirmed based on the received documentation, recoupment may occur.

    Provider and Claims Actions

    Documentation Required

    Document services and medical necessity

    CareSource may request documentation of services performed. Present appropriate and complete documentation at the time of review to validate medical necessity.

    Denial Risk

    WATS3D claims will be denied

    Claims for esophageal brush biopsy will be denied. CareSource considers esophageal brush biopsy using WATS3D experimental and investigational for screening, diagnosis, or surveillance of cancerous or pre-cancerous esophageal lesions due to insufficient evidence.

    Denial Risk

    Insufficient documentation may result in recoupment

    If the submitted documentation does not confirm medical necessity, recoupment may occur. Ensure appropriate and complete records are presented at the time of review.

    Clinical Background

    Barrett’s esophagus (BE) is a metaplastic change in the distal esophagus in which normal squamous epithelium is replaced by specialized columnar epithelium with goblet cells. It is associated with chronic gastroesophageal reflux disease (GERD); an estimated 5%–12% of patients with chronic GERD symptoms also have BE. Barrett’s esophagus is the only known precursor lesion of esophageal adenocarcinoma (EAC), contributing to the clinical importance of accurate esophageal lesion assessment.

    Key Definitions

    Barrett's esophagus (BE)
    DefinitionA pre-malignant condition of the esophagus that places patients at risk for esophageal adenocarcinoma (EAC).
    Underlying changeThe normal squamous epithelium is replaced by specialized columnar epithelium with goblet cells, a metaplastic change of the distal esophagus.
    Cancer relationshipBarrett's esophagus is the only known precursor lesion of esophageal adenocarcinoma.
    Esophageal adenocarcinoma (EAC)
    DefinitionOne of the two most common types of esophageal cancer.
    AbbreviationEAC stands for esophageal adenocarcinoma.
    Relationship to squamous cell carcinoma
    Policy Summary
    PayerCareSource Georgia
    PolicyEsophageal Brush Biopsy
    Policy CodePolicy MP-AD-1398
    Change TypeAdministrative updateno material clinical or coverage change
    Effective DateDecember 1, 2026
    Next Review DateN/A
    Key ActionPresent complete service and medical-necessity documentation when requested by CareSource.
    SourceLink
    On This Page
    Coverage CriteriaProvider and Claims ActionsClinical BackgroundKey Definitions
    Esophageal adenocarcinoma is identified alongside squamous cell carcinoma as one of the two most common types of esophageal cancer.
    Gastroesophageal reflux disease (GERD)
    DefinitionA condition occurring when a muscle at the end of the esophagus does not close properly.
    Reflux mechanismImpaired closure allows stomach contents to leak back, or reflux, into the esophagus.
    EffectRefluxed stomach contents irritate the esophagus.
    WATS3D
    Full nameWide-area transepithelial sampling with computer-assisted three-dimensional analysis.
    Sampling methodA computer-assisted biopsy technique used during endoscopy to sample esophageal tissue.
    Brush techniqueUses an abrasive brush designed to consistently sample deeper layers of the more firmly attached glandular epithelium found in Barrett's esophagus.